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Original Article
Detecting Invasive Fungal Disease in Surgical Patients:
Utility of the (13)- b-d-Glucan Assay
Jeffrey Skubic,1 Sharven Taghavi,2 Manuel Castillo-Angeles,3
Ramsis Ramsis,4 Ali Salim,3 and Reza Askari3
Abstract
Background: The specificity and sensitivity of the (13)-b-d-glucan (BDG) assay in surgical patients needs
further investigation. We hypothesized that the BDG assay would have lower sensitivity/specificity compared
with that of medical patients.
Methods: We reviewed patients who had undergone laparotomy, gastrectomy, hepatectomy, or colectomy and
had a BDG assay post-operatively.
Results: A total of 71 patients met study criteria. There were 29 (40.8%) who had proven/probable invasive
fungal infection. Sensitivity for BDG level ‡80 diagnosed within one week of the assay draw was 77.3% (95%
confidence interval [CI], 54.6–92.2%), and specificity was 44.9% (95% CI, 30.7–59.8). The positive predictive
value was 38.6% (95% CI, 31.0–46.9%), and negative predictive value was 82.5% (95% CI, 65.7–91.0%). A
BDG assay result of 149 pg/mL had a classification rate of 63.4%. Therefore, a BDG assay result ‡150 pg/mL
has a sensitivity of 78.6% and a specificity of 41.4%.
Conclusion: A BDG assay can be useful for ruling out invasive fungemia in post-operative patients.
Keywords: b-d-glucan assay; invasive fungemia; surgical patients
Despite the advent of new anti-fungal agents [1],invasive fungal infections continue to carry a high
mortality rate [2,3]. The population at risk for invasive fungal
infection, because of potent iatrogenic immunosuppres-
sion for solid organ or hematopoietic stem transplantation,
continues to increase [4,5]. In addition, increasing use of
life sustaining-therapies in the intensive care unit (ICU) has
led to more nosocomial fungal infections [6,7]. Early diag-
nosis of invasive fungal infection is imperative because early
administration of anti-fungal medications can improve sur-
vival [8]. Prompt diagnosis of fungal infection, however,
remains a clinical challenge because it can often necessitate
invasive procedures or can be difficult to discern from fungal
colonization.
The 1-3- b-d-glucan (BDG) assay can be used as a serum
marker for many invasive fungal infections [9]. The BDG
assay is a component of the cell wall of most fungi, with the
exception of zygomycetes and cryptococci [10]. Previous
studies have shown that the BDG assay has good diagnostic
accuracy for invasive fungal infection [10]. Several studies
have been performed in both medical and surgical patients
showing the accuracy of BDG assay in the diagnosis of in-
vasive fungal infection [11–14]. We hypothesized that BDG
assay in surgical patients would have lower sensitivity and
specificity compared with that of medical patients.
Methods
Study population
All patients, age 18 and older, undergoing four common
operations (laparotomy, gastrectomy, hepatectomy, or co-
lectomy) between 2010 and 2014 at two academic medical
centers were reviewed retrospectively. Those patients who
had a BDG assay post-operatively within 30 days of oper-
ation were then identified. If multiple assays were per-
formed, the single highest level was selected. Patients were
classified as having either proven/probable invasive fungal
disease or as having possible/no invasive fungal disease based
on the European Organization for Research and Treatment
of Cancer–Mycoses Study Group classification [9]. All 29
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patients in the proven/probable invasive fungal disease had
blood culture results that were positive for fungus. Patients who
did not have a BDG assay during the same hospitalization or
who had a BDG assay more than 30 days post-operatively were
excluded.
The outcomes measured included development of invasive
fungal infection within seven days of testing and the devel-
opment of invasive fungal infection by the end of hospitali-
zation. We chose the seven-day period because we thought
that this would be enough time in which to diagnose a fungal
infection if one was present. A BDG assay level ‡80 pg/mL
was used as the cutoff for an elevated level as established in
previous studies [15,16].
Statistical analysis
All data analyses were performed using STATA 15.0
software (College Station, TX: StataCorp LP). Continuous
variables are presented as median with interquartile range,
and categoric variables are reported as percentages of the
total number of data points available for that field. The Mann-
Whitney test and Fisher exact test were used to analyze
continuous and categoric variables. Sensitivity, specificity,
positive likelihood ratio, and negative likelihood ratio were
also calculated using the pre-determined cutoff value. A re-
ceiver operating characteristic (ROC) curve analysis was
performed plotting sensitivity versus specificity and the area
under the curve was calculated. For this, different cutoff
values were used to determine the maximum sensitivity and
specificity.
Results
A total of 71 patients met study criteria. Of these, 29
(40.8%) had proven/probable invasive fungal infection; all
had blood culture results that were positive for fungus. Of
these, 22 (75.9%) received a diagnosis within one week after
BDG assay was performed and the remaining seven (24.1%)
before the end of hospitalization. A total of 42 (59.2%) pa-
tients had no/possible fungal infection.
Baseline patient characteristics
Baseline patient characteristics are shown in Table 1. When
comparing the two cohorts, there was no significant difference
with respect to patient age (28% vs. 33%, p = 0.88) or female
gender (28% vs. 21%, p = 0.40). A total of 48% of patients were
immunosuppressed, with no difference between the two co-
horts (38% vs. 55%, p = 0.27). The most common surgical
procedure performed was colectomy (42%), followed by lap-
arotomy (35%), hepatectomy (17%), and gastrectomy (4%).
Distribution of type of operation was not significantly different
when comparing the two cohorts, as shown in Table 1.
Elevated b-d-glucan Levels
Sensitivity of an elevated BDG level for invasive fungal
disease diagnosed within one week of the assay was 77.3%
(95% CI, 54.6–92.2%) as shown in Table 2. Specificity was
44.9% (95% CI, 30.7–59.8%) for patients with a diagnosis
within one week of assay performance. The positive predic-
tive value was 38.6% (95% CI, 31.0–46.9%), and negative
predictive value was 81.5% (95% CI, 65.7–91.0%) as shown
in Table 2.
Sensitivity of an elevated BDG level for invasive fungal
disease diagnosed by the end of hospitalization was 69.0% (95%
CI, 49.2–84.7%) as shown in Table 3. Specificity was 42.9%
(95% CI, 27.7–59.0%) for patients with a diagnosis diagnose by
the end of hospitalization. The positive predictive value was
45.5% (95% CI, 36.8–54.4%), and negative predictive value
was 66.7% (95% CI, 51.2 – 79.2%) as shown in Table 3.
ROC curve
The area under the ROC curve was 0.56. After testing
different cutoff values, a BDG assay result of 149 pg/mL had




Probable or Proven IFD
(n = 29)
Possible or No IFD
(n = 42) p
Total
(n = 71)
Age (median) 63 (54-68) 65 (54-70) 62 (46-70) 0.88 63 (46-68)
Female gender 22 (31%) 8 (28%) 14 (33%) 0.40 22 (31%)
Diabetic 17 (24%) 8 (28%) 9 (21%) 0.37 17 (24%)
Hemodialysis 13 (18%) 7 (24%) 6 (14%) 0.23 13 (18%)
Malignancy 15 (21%) 9 (31%) 6 (14%) 0.08 15 (21%)
Immunosuppression 34 (48%) 11 (38%) 23 (55%) 0.27 34 (48%)
Neutropenia 4 ( 6%) 3 (10%) 1 ( 2%) 0.18 4 ( 6%)
IVIG 1 ( 1%) 0 ( 0%) 1 ( 2%) 0.59 1 ( 1%)
GVHD 5 ( 7%) 0 ( 0%) 5 (12%) 0.07 5 ( 7%)
Transplant 25 (35%) 8 (28%) 17 (40%) 0.19 25 (35%)
Albumin 12 (17%) 7 (24%) 5 (12%) 0.15 12 (17%)
Laparotomy 25 (35%) 10 (34%) 15 (36%) 0.56 25 (35%)
Hepatectomy 12 (17%) 5 (17%) 7 (17%) 0.57 12 (17%)
Gastrectomy 3 ( 4%) 2 ( 7%) 1 ( 2%) 0.36 3 ( 4%)
Colectomy 30 (42%) 11 (38%) 19 (45%) 0.36 30 (42%)
IFD = invasive fungal disease; IVIG = intravenous immunoglobulin; GVHD = graft versus host disease.
Table 2. b-d-glucan Assay ‡80 pg/mL at <7 Days
Sensitivity 77.3% (54.6%–92.2%)
Specificity 44.9% (30.7%–59.8%)
Positive predictive value 38.6% (40.0%–46.9%)
Negative predictive value 81.5% (65.7%–91.0%)













































the highest classification rate of 63.4%. Therefore, a BDG
assay result ‡150 pg/mL has a sensitivity of 78.6% and a
specificity of 41.4%.
Discussion
Previous studies have shown that BDG levels can be a
useful adjunct for diagnosing many invasive fungal infec-
tions, whether in medical or surgical patients [10–14]. These
studies suggest that BDG should be used in patients with
appropriate pre-test probability and a clinical picture that can
be consistent with fungal infection. The BDG assays are still
helpful even when anti-fungal agents have been initiated.
While previous studies have shown that BDG assay may have
lower sensitivity in certain populations, such as those with
hematologic malignancy, little data exist regarding its sen-
sitivity and specificity in surgical patients [5,10,17]. Our
study demonstrated that the BDG assay has good sensitivity,
but low specificity in post-operative patients.
This study found that BDG assay in surgical patients has
good sensitivity, making it a useful adjunct for ruling out
many invasive fungal infections in patients who have had
recent operations. For patients with a diagnosis of invasive
fungal infection within seven days of elevated BDG assay,
sensitivity was found to be 77.3%. This finding is similar to
that found in medical patients where a large meta-analysis
determined that BDG assay has a sensitivity of 79.1% [10].
Previous studies have shown that sensitivity of BDG varies
among different subgroups. How this sensitivity differs among
different categories of surgical patients needs further charac-
terization. Patients with upper gastrointestinal perforations are
known to be at higher risk for invasive fungal infection. How a
BDG assay should be interpreted in a patient having elective
gastric resection may be different from an assay in a patient
who underwent emergency laparotomy for a perforated gastric
ulcer. Similar to the present study, previous studies performed
in surgical patients have been underpowered and unable to
determine whether the BDG assay is more accurate in patients
with specific types of operations [11–14].
While sensitivity for BDG assay in surgical patients ap-
pears to be high, the test is not specific in patients with recent
operations (44.9%). This is in contrast to previous studies that
have shown high specificity among the general population. A
meta-analysis determined that the pooled specificity after
analyzing 16 studies was 85.3% [10]. Factors known to cause
false positive results among BDG assays include medica-
tions, hemodialysis, and immunoglobulin therapies [18].
It is theorized that exposure to surgical gauze may be an-
other cause of false positive results. Kanamori et al. [19] ex-
posed purified water to six different types of commonly used
surgical gauze ex-vivo; in all samples but one, markedly el-
evated BDG levels were measured. The high false positive
rate among surgical patients needs further investigation. De-
termining what other factors are contributing to false positive
results in surgical patients may allow clinicians to better select
patients who may benefit from a BDG assay.
While BDG assay value ‡80 pg/mL has good sensitivity,
our findings of a low area under the ROC curve suggest that
an optimal cutoff value for the BDG assay does not exist in
surgical patients. Further studies are needed to determine
whether a cutoff different from that typically used in medical
patients should be used in surgical patients suspected of in-
vasive fungemia. While specificity for BDG assay in surgical
patients is poor overall, our findings do indicate that a BDG
value ‡150 pg/mL has good specificity (78.6%) for diag-
nosing invasive fungal infections.
This study had several limitations, including those related
to two-institution, retrospective analysis. All data were ob-
tained from chart review, which introduces selection bias and
some incomplete data collection. Because one of the inclu-
sion criteria for the study was the requirement of a BDG
assay, there is a significant selection bias for patients included
in the study. In addition, this analysis had a small sample size,
thus limiting the power of the study. Patients did not have a
BDG assay on a daily basis; therefore, we could not deter-
mine median time from BDG assay to infection.
Because of the retrospective nature of the study, we could
not examine other factors for fungemia such as total parenteral
nutrition, colonization sites, or exposure to carbepenems. The
study is also limited by surgeon preferences, because some
surgeons may be more likely to order a BDG assay early in the
hospital course, while others may fail to order the assay even
when warranted.
Conclusion
This study demonstrates high sensitivity and low specificity
of the BDG assay in surgical patients. A BDG assay can be
useful for ruling out invasive fungemia in post-operative patients
because it has high sensitivity and negative predictive value. Its
poor specificity and positive predictive value, however, suggests
that patients with a positive assay must have further investiga-
tion in determining whether anti-fungal agents should be initi-
ated. When the BDG assay values are very high (‡150 pg/mL) in
surgical patients, however, the test has good specificity for in-
vasive fungemia and anti-fungal agents should be initiated.
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